All News

labs2.jpg

MDA-5 Antibodies and Juvenile Dermatomyositis

Jack Cush, MD

A multicentre, retrospective study examined MSA profiles (by immunoprecipitation) from 96 juvenile idiopathic inflammatory myopathies (JIIM) at nine pediatric rheumatology centres in Japan. MSA were found in 85 of 96 cases with over 90% of patients having one of the following three MSA

Read Article
RheumNow Podcast square

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
cancer search news magnify

High Risk Cancer Profiling with Inflammatory Myositis

Jack Cush, MD

A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).

Read Article
podcast logo

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article
2020 Year Review

2020 Rheumatology Year in Review

Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
Jo1.gottrons.jpg

ProDERM Study: IVIG in Dermatomyositis

Jack Cush, MD

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article
News Feature: MDA-5 Antibodies and Juvenile Dermatomyositis https://t.co/vxyXZyO0gs https://t.co/GgzhnhlmdR

Links:

Dr. John Cush RheumNow ( View Tweet)
Other than anti-tRNA synthetase Abs, there are several new Abs associated with PM/DM @UTSWNews @UTSWInternalMed https://t.co/EttRB3YYHm
Dr. John Cush RheumNow ( View Tweet)
Classic path findings in dermatomyositis @UTSWNews @UTSWInternalMed https://t.co/W61OveDSwG
Dr. John Cush RheumNow ( View Tweet)
An unsual type of adult polymyositis that is not usually steroid responsive - Polymyositis with mitochondrial abnormalities - older patients +COX staining, slow progression. @UTSWNews @UTSWInternalMed https://t.co/2tv1R3e9Qg
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Grand Rounds with Dr. Dennis Burns - lecturing on neuropathology of inflammatory myositis. Not all Muscle Bxs are positive, estimated sampling error w/ normal findings in 10-15% @UTSWNews @UTSWInternalMed https://t.co/Xm73GuMa3j
Dr. John Cush RheumNow ( View Tweet)
High Risk Cancer Profiling with Inflammatory Myositis A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs). https://t.co/TjmdGtdDQG https://t.co/tlfVU031fY

Links:

Dr. John Cush RheumNow ( View Tweet)
Canadian lupus cohort of 560 SLE pts without myositis at baseline. Over time, only 5 pts developed myositis (after mean 8.5 yrs). Incidence = 1.05 per 1000 PYs. Arthritis, Raynauds, -Sm Abs were common, but only non-Whites had increased risk of myositis. https://t.co/fzWhUADjMz

Links:

Dr. John Cush RheumNow ( View Tweet)

44 pts of Inclusion body myositis were randomized to either PBO or sirolimus 2 mg/d. At 12 mos there were no signif differences betw groups for motor strength , but sirolimus had more SAEs (45 vs 27%); yet sirolimus had better HAQ, FVC & 6-min walk times. https://t.co/YhnRTnaGFl

Links:

Dr. John Cush RheumNow ( View Tweet)

ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/HOB8CYn9yc https://t.co/AmT3AQdawa

Links:

Dr. John Cush RheumNow ( View Tweet)
44 patient study of sirolimus vs placebo in patients with inclusion body myositis found no difference in the primary outcome of relative knee extension strength, nor in secondary outcomes. SAE were more common w/ sirolimus 45% vs 27% in PBO https://t.co/YhnRTnaGFl

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @drdavidliew :The 'triple M' irAEs (myositis/myocarditis/MG): one of the rheumatic irAEs where autoAb are freq pos Nice systematic review: any autoAb+ 61% tested MG+ 59% tested MSA+ in 27% tested (18/67, 11 had myositis alone) https://t.co/aQHapPbjw9
Dr. John Cush RheumNow ( View Tweet)
IVIg in Dermatomyositis: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0995 presented at #ACR20. https://t.co/PKYATqUh0d

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch our #ACR20 video recap titled "Treatment of Dermatomyositis Studies" with Dr Robert Chao (@doctorRBC). Dr. Chao reviews two important abstracts - #0955 and #0958 - on the treatment of dermatomyositis as presented at the 2020 ACR annual meeting. https://t.co/1hiTZQVjlL https://t.co/CW9OGHTuJg

Links:

Dr. John Cush RheumNow ( View Tweet)
Summary of #ACR20 part C: - A must see talk was the avacopan story - IVIG for myositis does work! More than just anecdotal evidence now - DIET is key to helping improve autoimmune dz! - low dz activity RA pts should taper off of MTX 1st when also on TNFi @jeffsparks @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×